Why talk of a pharma patent deal-making surge in 2018 is premature

A flurry of pharmaceuticals transactions in January has led several observers to describe the past month as the best start to M&A in recent years, and has further encouraged predictions of a surge in patent-driven acquisitions in 2018.

Yet, by a…

Unlock unlimited access to all IAM content